Trial Profile
A Phase 1 Open-label Study To Characterize The Pharmacokinetics Of A Single 45 Mg Oral Dose Of Dacomitinib (Pf-00299804) In Healthy Chinese Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Sep 2018
Price :
$35
*
At a glance
- Drugs Dacomitinib (Primary)
- Indications Brain metastases; Gastric cancer; Glioblastoma; Non-small cell lung cancer; Orofacial cancer; Squamous cell cancer
- Focus Pharmacokinetics
- Sponsors Pfizer
- 24 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Sep 2014 Planned End Date changed from 31 Aug 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.
- 09 Sep 2014 Planned primary completion date changed from 31 Aug 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.